Copyright
©The Author(s) 2019.
World J Clin Oncol. Dec 24, 2019; 10(12): 391-401
Published online Dec 24, 2019. doi: 10.5306/wjco.v10.i12.391
Published online Dec 24, 2019. doi: 10.5306/wjco.v10.i12.391
Table 1 Clinical and nutritional characteristics of the sample at baseline
Characteristics | n = 22 |
Age (yr, mean value) | 61 |
Weight (kg, mean value ± SD) | 64 ± 14.2 |
BMI (mean value ± SD) | 25 ± 5.2 |
Allergies, n (%) | |
Yes | 15 (68.2) |
No | 7 (31.8) |
Smoke, n (%) | |
Yes | 5 (22.7) |
No | 17 (77.3) |
Alcohol, n (%) | |
Yes | 8 (36.4) |
No | 14 (63.6) |
Type of gynecological cancer, n (%) | |
Cervical cancer | 5 (22.7) |
Endometrial cancer | 2 (9.1) |
Ovarian cancer | 15 (68.2) |
Chemotherapy treatment, n (%) | |
Carboplatin | 2 (9.2) |
Carboplatin - Bevacizumab | 1 (4.5) |
Carboplatin - Caelyx | 3 (13.6) |
Carboplatin - Gemcitabine | 2 (9.2) |
Carboplatin - Taxol | 9 (40.9) |
Carboplatin - Gemcitabine - Bevacizumab | 1 (4.5) |
Cisplatin | 3 (13.6) |
Cisplatin – Bevacizumab | 1 (4.5) |
Number of lines, n (%) | |
I | 14 (63.6) |
II | 7 (31.8) |
III | 1 (4.6) |
Nutritional requirements | |
BEE in kcal (Average value ± SD) | 1262.5 ± 146.6 |
TEE in kcal (Average value ± SD) | 1678.9 ± 177.1 |
Mediterranean diet adherence | |
MDSS (mean value ± SD) | 12.5 ± 3.4 |
MDSS ≥ 13, n (%) | 12 (54.5) |
MDSS < 13 | 10 (45.5) |
Table 2 Anthropometric and nutritional characteristics of the two groups at the baseline according to the Mediterranean diet adherence score
MDSS ≥ 13 | MDSS < 13 | Total | |
(n = 12) | (n = 10) | (n = 22) | |
Age (yr, mean value ± SD) | 64.9 ± 11.6 | 56.4 ± 11.9 | 61 ± 12.2 |
Weight (kg, mean value ± SD) | 61.3 ± 11.4 | 67.2 ± 17 | 64 ± 14.2 |
BMI (mean value ± SD) | 24.5 ± 4.3 | 25.7 ± 6.3 | 25 ± 5.2 |
MDSS (mean value ± SD) | 15.1 ± 2.1 | 9.5 ± 1.7 | 12.5 ± 3.4 |
Average daily intake | |||
Proteins (g, mean value ± SD) | 67.8 ± 15.6 | 83.5 ± 32 | 74.9 ± 25.1 |
Fats (g, mean value ± SD) | 73.7 ± 21.9 | 91.6 ± 41.2 | 81.8 ± 32.6 |
Saturated fats (g, mean value ± SD) | 25.8 ± 7.4 | 33.1 ± 19.9 | 29.1 ± 14.6 |
Carbohydrates (g, mean value ± SD) | 227.5 ± 37.7 | 208.3 ± 80 | 218.8 ± 59.8 |
Sugars (g, mean value ± SD) | 91 ± 15 | 85,9 ± 29 | 88,7 ± 22 |
Fibers (g, mean value ± SD) | 22 ± 4.5 | 17.3 ± 6 | 19.9 ± 5.6 |
Energy intake (kcal, mean value ± SD) | 1893.3 ± 376.3 | 2038.7 ± 724.8 | 1959.4 ± 552.1 |
Fluid intake (mL, mean value ± SD) | 1320.8 ± 491.5 | 1365 ± 704 | 1340.9 ± 582.6 |
Coverage of the TEE (mean % ± SD) | 115.8 ± 20.2 | 117.7 ± 41.6 | 116.7 ± 30.9 |
Coverage of the TEE > 100%, n (%) | 10 (83.3) | 5 (50) | 15 (68.2) |
Table 3 Nutritional-anthropometric features derived from the analysis of the second food frequency questionnaire
MDSS ≥ 13 | MDSS < 13 | Total | |
(n = 12) | ( n = 10) | ( n = 22) | |
Weight (kg, mean value ± SD) | 61 ± 11.3 | 67.2 ± 17.3 | 63.8 ± 14.3 |
BMI (mean value ± SD) | 24.4 ± 4.3 | 25.7 ± 6.3 | 25 ± 5.2 |
MDSS (mean value ± SD) | 13.3 ± 0.8 | 8.9 ± 2.6 | 11.3 ± 2.9 |
Average daily intake | |||
Proteins (g, mean value ± SD) | 56.1 ± 15.5 | 70.6 ± 34.2 | 62.7 ± 26.1 |
Fats (g, mean value ± SD) | 60.6 ± 17.8 | 83 ± 29 | 70.8 ± 25.6 |
Saturated fats (g, mean value ± SD) | 21.3 ± 6.6 | 27.5 ± 12 | 24.1 ± 9.7 |
Carbohydrates (g, mean value ± SD) | 212.5 ± 55.9 | 215 ± 95.6 | 213.6 ± 74.5 |
Sugars (g, mean value ± SD) | 87.9 ± 20.6 | 99 ± 37.9 | 93 ± 29.5 |
Fibers (g, mean value ± SD) | 18.3 ± 5.5 | 18.7 ± 8.3 | 18.5 ± 6.8 |
Energy intake (kcal, mean value ± SD) | 1633.8 ± 406.8 | 1921.7 ± 687.7 | 1764.6 ± 557.5 |
Fluid intake (mL, mean value ± SD) | 1400 ± 495.5 | 1388.9 ± 416.7 | 1394.7 ± 427.5 |
Coverage of the TEE (%, mean value ± SD) | 100.2 ± 24.5 | 110.4 ± 36.4 | 104.8 ± 30.1 |
Coverage of the TEE > 100%, n (%) | 7 (58.3) | 5 (50) | 12 (54.5) |
Table 4 Gastrointestinal toxicities’ score after first chemotherapy cycle in the whole study population and in the two study’s groups according to the Mediterranean diet serving score
MDSS ≥ 13 | MDSS < 13 | Total | P value | |
Dry mouth (G) | 1 ± 1.3 | 1.1 ± 1.3 | 1 ± 1.3 | 0.85 |
Dysphagia (G) | 0.3 ± 0.5 | 0.4 ± 0.7 | 0.3 ± 0.6 | 0.70 |
Oral sores (A) | 0.2 ± 0.4 | 0.5 ± 1.3 | 0.3 ± 0.9 | 0.45 |
Oral sores (G) | 0.1 ± 0.3 | 0.4 ± 1.3 | 0.2 ± 0.9 | 0.44 |
Mouth’s cracks (G) | 0.1 ± 0.3 | 0.4 ± 1.3 | 0.2 ± 0.9 | 0.44 |
Dysgeusia (G) | 0.9 ± 1.2 | 1 ± 1.2 | 1 ± 1.2 | 0.84 |
Loss of appetite (I.A) | 1.1 ± 1.1 | 1.4 ± 1.5 | 1.2 ± 1.3 | 0.59 |
Loss of appetite (G) | 1 ± 1 | 1.3 ± 1.7 | 1.1 ± 1.3 | 0.61 |
Nausea (F) | 1.5 ± 1.1 | 1.4 ± 1.6 | 1.5 ± 1.3 | 0.86 |
Nausea (G) | 1 ± 0.9 | 1.5 ± 1.7 | 1.2 ±1.3 | 0.38 |
Vomiting (F) | 0.6 ± 0.8 | 0.6 ± 1.3 | 0.6 ± 1 | 1 |
Vomiting (G) | 0.3 ± 0.5 | 0.6 ± 1.3 | 0.5 ± 1 | 0.46 |
Stomachache (F) | 0.2 ± 0.6 | 0.7 ± 0.9 | 0.4 ± 0.8 | 0.13 |
Stomachache (G) | 0.1 ± 0.3 | 0.5 ± 0.7 | 0.3 ± 0.6 | 0.08 |
Intestinal gas (yes/no) | 0.4 ± 0.5 | 0.3 ± 0.5 | 0.4 ± 0.5 | 0.64 |
Bloating (F) | 0.7 ± 0.9 | 0.5 ± 1 | 0.6 ± 0.9 | 0.62 |
Bloating (G) | 0.3 ± 0.5 | 0.4 ± 0.7 | 0.4 ± 0.6 | 0.70 |
Constipation (G) | 0.5 ± 0.5 | 0.7 ± 0.7 | 0.6 ± 0.6 | 0.44 |
Diarrhea (F) | 0.7 ± 0.9 | 0.7 ± 1.3 | 0.7 ± 1.1 | 1 |
Abdomen ache (F) | 1.1 ± 1 | 0.3 ± 0.7 | 0.7 ± 0.9 | 0.04 |
Abdomen ache (G) | 0.8 ± 0.8 | 0.2 ± 0.4 | 0.5 ± 0.7 | 0.04 |
Abdomen ache (I.A) | 0.7 ± 0.8 | 0.2 ± 0.6 | 0.5 ± 0.7 | 0.11 |
Toxicity (TOT) | 13.4 ± 6.6 | 15.1 ± 14.5 | 14.2 ± 10.7 | 0.7 |
Table 5 Gastrointestinal toxicities’ score after last chemotherapy cycle in the whole study population and in the two study’s groups according to the Mediterranean diet serving score
MDSS ≥ 13 | MDSS < 13 | Total | P value | |
Dry mouth (G) | 1.5 ± 1.8 | 0.8 ± 1.8 | 1.2 ± 1.7 | 0.53 |
Dysphagia (G) | 0 ± 0 | 0.2 ± 0.4 | 0.1 ± 0.3 | 0.24 |
Oral sores (G) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 1 |
Oral sores (A) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 1 |
Mouth’s cracks (G) | 0 ± 0 | 0.2 ± 0.4 | 0.1 ± 0.3 | 0.24 |
Dysgeusia (G) | 1.3 ± 1.5 | 2.6 ± 1.9 | 1.9 ± 1.8 | 0.23 |
Loss of appetite (G) | 1.3 ± 1.5 | 2.4 ± 1.7 | 1.8 ± 1.6 | 0.28 |
Loss of appetite (I.A) | 1.3 ± 1.5 | 2 ± 1.4 | 1.6 ± 1.4 | 0.44 |
Nausea (F) | 0.7 ± 1.6 | 3.6 ± 0.9 | 2 ± 2 | < 0.01 |
Nausea (G) | 0.7 ± 1.6 | 3.4 ± 0.9 | 1.9 ± 1.9 | < 0.01 |
Vomiting (F) | 0.3 ± 0.8 | 0.8 ± 1.3 | 0.5 ± 1 | 0.45 |
Vomiting (G) | 0.2 ± 0.4 | 1 ± 1.7 | 0.5 ± 1.2 | 0.28 |
Stomach ache (F) | 0 ± 0 | 1 ± 1 | 0.5 ± 0.8 | 0.03 |
Stomach ache (G) | 0 ± 0 | 1.2 ± 1.3 | 0.5 ± 1 | 0.04 |
Gas (yes/no) | 0.3 ± 0.5 | 0.4 ± 0.5 | 0.4 ± 0.5 | 0.74 |
Bloating (F) | 0 ± 0 | 1.4 ± 1.3 | 0.6 ± 1.1 | 0.02 |
Bloating (G) | 0 ± 0 | 1 ± 1 | 0.5 ± 0.8 | 0.03 |
Constipation (G) | 0.8 ± 0.4 | 2.4 ± 1.8 | 1.5 ± 1.4 | 0.06 |
Diarrhea (F) | 0.5 ± 0.8 | 1.2 ± 1.1 | 0.8 ± 1 | 0.25 |
Abdomen ache (F) | 0.2 ± 0.4 | 1.4 ± 0.9 | 0.7 ± 0.9 | 0.01 |
Abdomen ache (G) | 0.2 ± 0.4 | 1.2 ± 0.8 | 0.6 ± 0.8 | 0.02 |
Abdomen ache (I.A) | 0.2 ± 0.4 | 1.2 ± 0.8 | 0.6 ± 0.8 | 0.02 |
GI toxicity (TOT) | 9.5 ± 10.9 | 29.4 ± 10.4 | 18.5 ± 14.5 | 0.01 |
- Citation: Ghisoni E, Casalone V, Giannone G, Mittica G, Tuninetti V, Valabrega G. Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience. World J Clin Oncol 2019; 10(12): 391-401
- URL: https://www.wjgnet.com/2218-4333/full/v10/i12/391.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i12.391